ANI Pharmaceuticals, Inc. (ANIP) key performance indicators and operating metrics (10 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Adjusted Diluted Earnings per Share (Non-GAAP) | 2.05 USD_per_share | FY2026-Q1 |
| Adjusted Non-GAAP Earnings Before Interest, Taxes, Depreciation and Amortization | 63M | FY2026-Q1 |
| Brands Net Revenues | 12.3M | FY2026-Q1 |
| Non-GAAP Gross Margin | 60.80 percent | FY2026-Q1 |
| GAAP Gross Margin | 60.60 percent | FY2026-Q1 |
| Generics Pharmaceutical Products Net Revenues | 105.4M | FY2026-Q1 |
| Rare Disease and Brands Net Revenues | 128.2M | FY2026-Q1 |
| Total Rare Disease Net Revenues | 94.4M | FY2026-Q1 |
| Total Company Net Revenues Guidance 2025 | 237.5M | FY2026-Q1 |
| Acute Gouty Arthritis Flares Share of Cortrophin Gel Usage | 15.00 percent | FY2025-Q3 |
Back to ANIP overview · ANIP earnings · ANIP holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.